HOME
Leading the way to a cure

LUPUS NEWS

New Hope for Lupus Patients

January 25, 2013

A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France. The peptide, known as P140/LupuzorTM, is well tolerated by patients and leads to regression of the disease. Under the CNRS patent, ImmuPharma-France, which funded the trial, has an exclusive license to use the peptide. Now the final phase of clinical tests should soon confirm these results and contribute to the development of a drug without the side effects of existing treatments, which use cortico-steroids and immunosuppressants. These results are published online in the Annals of the Rheumatic Diseases.

Lupus is an autoimmune disease that affects 5 million people worldwide, mostly young women, and against which there is only non-specific, palliative treatment. In 2003, Sylviane Muller's team designed a peptide known as P140 (1) that proved capable of delaying the development of lupus in a mouse model (2). Since then, several regulatory clinical trials have been carried out by ImmuPharma-France, under CNRS license.

***

Click here to read the full article.

Source: News-Medical.net


New Hope for Lupus Patients

January 25, 2013

A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France. The peptide, known as P140/LupuzorTM, is well tolerated by patients and leads to regression of the disease. Under the CNRS patent, ImmuPharma-France, which funded the trial, has an exclusive license to use the peptide. Now the final phase of clinical tests should soon confirm these results and contribute to the development of a drug without the side effects of existing treatments, which use cortico-steroids and immunosuppressants. These results are published online in the Annals of the Rheumatic Diseases.

Lupus is an autoimmune disease that affects 5 million people worldwide, mostly young women, and against which there is only non-specific, palliative treatment. In 2003, Sylviane Muller's team designed a peptide known as P140 (1) that proved capable of delaying the development of lupus in a mouse model (2). Since then, several regulatory clinical trials have been carried out by ImmuPharma-France, under CNRS license.

***

Click here to read the full article.

Source: News-Medical.net



1.5 million

people in the U.S. have Lupus.

90 million

dollars committed to lupus research by the Alliance for Lupus Research.


We're walking across the United States to raise awareness and funds for lupus research.

Can't make it? Join our National Virtual Walk to participate anytime, anywhere.


Show your support by visiting the Alliance for Lupus Research online store. Discover the perfect gift, or prepare for a walk with our selection of apparel and accessories.

Powered by Convio
nonprofit software